Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022665 | 1.00 | STING1 (0.60) | STING1ABCB1HTTGAAKDM4E | |
| SCHEMBL8643080 | 1.00 | STING1 (0.60) | STING1ABCB1HTTGAAKDM4E | |
| SCHEMBL146378 | 0.85 | KIF11 (0.66) | STING1ABCB1KDM4EALDH1A1HPGD | |
| SCHEMBL29726990 | 0.85 | KIF11 (0.66) | STING1ABCB1KDM4EALDH1A1HPGD | |
| Ammonia Solution, Strong SCHEMBL28022012 | 0.84 | KIF11 (0.63) | STING1ABCB1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL572039 | 0.84 | KIF11 (0.63) | STING1ABCB1KDM4EALDH1A1HPGD | |
| SCHEMBL21027577 | 0.83 | HTT (0.53) | STING1ABCB1HTTGAAKDM4E | |
| SCHEMBL13425978 | 0.83 | MAOA (0.54) | STING1ABCB1HTTGAAKDM4E | |
| SCHEMBL14116119 | 0.82 | KIF11 (0.72) | ABCB1HTTGAAKDM4EALDH1A1 | |
| SCHEMBL14552258 | 0.80 | ALDH1A1 (0.68) | ABCB1HTTGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329746-B2 | AR+breast cancer treatment methods | ELLIPSES PHARMA LTD (GB) | 2025-06-17 | — | — | US | claimed |
| US-20250129163-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-24 | — | — | US | claimed |
| US-20250114450-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-10 | — | — | US | claimed |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | WISTAR INST (US) | 2025-01-09 | — | — | US | claimed |
| US-20240207234-A1 | AR+BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2024-06-27 | — | — | US | claimed |
| EP-4321537-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2024-02-14 | — | — | EP | claimed |
| WO-2023246247-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中山康方生物医药有限公司 | 2023-12-28 | — | — | WO | claimed |
| CN-117257934-A | Pharmaceutical composition and use thereof | 中山康方生物医药有限公司 | 2023-12-22 | — | — | CN | claimed |
| EP-4190819-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2023-06-07 | — | — | EP | claimed |
| CN-115702934-A | Combination of an MCL-1 inhibitor and an inhibitor of a member of the DNA damage response pathway | 江苏恒瑞医药股份有限公司 | 2023-02-17 | — | — | CN | claimed |
| CN-217928281-U | Comprehensive sequential hydrogenation control system | 上海氢枫能源技术有限公司 | 2022-11-29 | — | — | CN | claimed |
| EP-4066827-A1 | AR+ BREAST CANCER TREATMENT METHODS | Ellipses Pharma Ltd (GB) | 2022-10-05 | — | — | EP | claimed |
| CN-115068603-A | Pharmaceutical combination containing anti-PD-1-anti-VEGFA bispecific antibody and application thereof | 中山康方生物医药有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2022188832-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | 中山康方生物医药有限公司 | 2022-09-15 | — | — | WO | claimed |
| CN-110907559-B | Universal fixed bed catalyst evaluation device | 武汉纺织大学 | 2022-04-08 | — | — | CN | claimed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | claimed |
| EP-4096651-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122036912-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | STING1 659/4885ABCB1 384/4885HTT 377/4885 |
| US-20240207234-A1 | AR+BREAST CANCER TREATMENT METHODS | BRCA1, AR, PARP6 | STING1 1110/4885ABCB1 1275/4885HTT 2105/4885 |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | STING1 2389/4885ABCB1 2007/4885HTT 3725/4885 |
| US-12329746-B2 | AR+breast cancer treatment methods | BRCA1, AR, PARP6 | STING1 1110/4885ABCB1 1275/4885HTT 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.